Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SYX-1042 by Eli Lilly and Co for Inflammation: Likelihood of Approval
SYX-1042 is under clinical development by Eli Lilly and Co and currently in Phase I for Inflammation. According to GlobalData,...
SYX-1042 by Eli Lilly and Co for Autoimmune Disorders: Likelihood of Approval
SYX-1042 is under clinical development by Eli Lilly and Co and currently in Phase I for Autoimmune Disorders. According to...
SYX-1042 by Eli Lilly and Co for Multiple Sclerosis: Likelihood of Approval
SYX-1042 is under clinical development by Eli Lilly and Co and currently in Phase I for Multiple Sclerosis. According to...